Treatment targets in the management of dyslipidemias: Which targets in whom?

Current Cardiology Reports

Volumn 14, Issue 6, 2012, Pages 692-700

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

AtheroscleroticCVD; Bile acid sequestrants; CETP inhibitors; CKD; Diabetes; Dyslipidemia; Ezetimibe; Fibrates; Lifestyle; Metabolic syndrome; Nicotinic acid; Obesity; PCSK9 inhibitors; Physical activity; Secondary and primary prevention; Smoking; Statins

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; PHARMACOLOGICAL BLOCKING; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT INDICATION;

AGE FACTORS; ATHEROSCLEROSIS; DIET, FAT-RESTRICTED; DYSLIPIDEMIAS; EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; SMOKING CESSATION; STROKE;

EID: 84870481730     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0305-7     Document Type: Article

References (68)

1. NCEP Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
2. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-72.
3. Grundy SM, Wilhelmsen L, Rose G, et al. Coronary heart disease in high-risk populations: lessons from Finland. Eur Heart J. 1990;11:462-71.
4. Pietinen P, Lahti-Koski M, Vartiainen E, et al. Nutrition and cardiovascular disease in Finland since the early 1970s: a success story. J Nutr Health Aging. 2001;5:150-4.
5. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-41.
6. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997;96:3248-50.
7. Kones R. Is prevention a fantasy, or the future of medicine? a panoramic view of recent data, status, and direction in cardiovascular prevention. Ther Adv Cardiovasc Dis. 2011;5:61-81.
8. Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥18 years-United States, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60:1207-12.
9. WHO. Report on the global tobacco epidemic: the MPOWER package. Geneva; 2008.
10. Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. Expert Rev Cardiovasc Ther. 2008;6:883-95.
11. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569-82.
12. Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012; [Epub ahead of print].
13. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;376:1670-81.
14. Gutierrez J, Ramirez G, Rundek T, et al. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based metaanalysis statin therapy to prevent recurrent CVevents. Arch Intern Med. 2012;172:909-19.
15. Abramson J, Wright JM. Are lipid-lowering guidelines evidencebased? Lancet. 2007;369:168-9.
16. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med. 2008;359:2195-207.
17. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-64.
18. Vega GL, Dunn FL, Grundy SM. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol. 2011;108:1129-35.
19. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-55.
20. Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005;95:254-7.
21. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol. 2008;101:58B-62B.
22. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243-50.
23. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.
24. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 1987;83:9-20.
25. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875-84.
26. Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492-8.
27. Bays HE, Moore PB, Drehobl MA, Ezetimibe Study Group, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001;23:1601-30. Erratum in: Clin Ther. 2001;23:1601.
28. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-56.
29. Cannon CP, Giugliano RP, Blazing MA, IMPROVE-IT Investigators, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin vs simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826-32.
30. Bays HE, Shah A, Macdonell G, et al. Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. Metab Syndr Relat Disord. 2011;9:135-42.
31. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-18.
32. Cannon CP, Shah S, Dansky HM, et al. Determining the efficacy and tolerability investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-15.
33. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413-9.
34. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148-56.
35. Bryzgalova G, Effendic S, Khan A, et al. Anti-obesity, antidiabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol. 2008;111:262-7.
36. Suckling K. Phospholipase A2s: developing drug targets for atherosclerosis. Atherosclerosis. 2010;212:357-66.
37. Cohen JC, Boerwinkle E, Mosley Jr TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-72.
38. Smith Jr SC, Benjamin EJ, Bonow RO, World Heart Federation and the Preventive Cardiovascular Nurses Association, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458-73.
39. Catapano AL, Reiner Z, De Backer G, European Society of Cardiology (ESC); European Atherosclerosis Society (EAS), et al. ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3-46.
40. Amarenco P, Bogousslavsky J, Callahan III A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59.
41. Amarenco P, Labreuche J, Lavallée P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902-9.
42. D'Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-53.
43. Conroy R, Pyorala K, Fitzgerald AP, et al. Estimation of 10 year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
44. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin meta-analysis of individual data from 27 randomized trials. Lancet. [published online May 16, 2012].
45. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35 Suppl 1:S11-63.
46. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care. 2009;32:493-8.
47. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
48. Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Curr Opin Lipidol. 2011;22:55-61.
49. Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012;156:570-81.
50. Wanner C, Krane V, März W, German Diabetes and Dialysis Study Investigators, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-48. Erratum in: N Engl J Med. 2005;353:1640.
51. Fellström BC, Jardine AG, Schmieder RE, for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407.
52. Holdaas H, Fellström B, Jardine AG, on behalf of the Assessment of LEscol in Renal Transplantation (ALERT). Study investigates effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomized, placebo-controlled trial. Lancet. 2003;361:2024-31.
53. Baigent C, Landray MJ, Reith C, SHARP Investigators, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181-92.
54. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
55. Grundy SM, Cleeman JI, Daniels SR, American Heart Association; National Heart, Lung, and Blood Institute, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52. Erratum in: Circulation. 2005;112:e298. Circulation. 2005;112:e297. PubMed PMID: 16157765.
56. Deedwania P, Barter P, Carmena R, Treating to New Targets (TNT) Investigators, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919-23.
57. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59:635-43.
58. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
59. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55:1310-7.
60. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(Suppl M):M8-M14.
61. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol. 2009;20:497-504.
62. Isaacsohn J, Hunninghake D, Schrott H, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003;26:18-24.
63. Shepherd J, Blauw GJ, Murphy MB, PROspective Study of Pravastatin in the Elderly at Risk, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623-30.
64. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. Br Med J. 2009;338:b2376.
65. Downs JR, Clearfield M, Whitney E, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-22.
66. Kathiresan S, Myocardial Infarction Genetics Consortium. A PCSK9 missense variant associated with a reduced risk of earlyonset myocardial infarction. N Engl J Med. 2008;358:2299-300.
67. Brown MS, Goldstein JL. Biomedicine. Lowering LDL-not only how low, but how long? Science. 2006;311:1721-3.
68. Domanski M, Lloyd-Jones D, Fuster V, et al. Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol. 2011;8:721-5.